Science · Health
At last, a drug treats the cause of type 1 narcolepsy, not just the symptoms
The FDA has approved Orzeyful, the first medicine that restores the signal keeping people with type 1 narcolepsy awake. A target science had been chasing since 1998.
People with type 1 narcolepsy do not drop off because they are tired: they are missing orexin, the molecule the brain uses to keep you awake. For decades, treatments only covered up one symptom at a time — the daytime sleep, the attacks of muscle weakness. On 5 August 2026, the FDA approved the first one that goes to the root.
First, the basics: narcolepsy is a chronic neurological sleep disorder. Someone who has it cannot control when they fall asleep, and suffers irresistible sleep attacks during the day however much rest they have had. Type 1 adds cataplexy: a sudden loss of muscle tone set off by a strong emotion — a laugh, a fright — that can drop a person to the floor wide awake.
The drug is called oveporexton (sold as Orzeyful, by Takeda) and it does what none of the others did: instead of offsetting the symptoms, it restores the missing signal. Type 1 narcolepsy sets in when the brain loses the neurons that make orexin; without it, the switch that keeps you awake never fully flips. Oveporexton is a “selective orexin receptor 2 agonist”: it takes the place of the absent molecule at the receptor and turns that switch back on.
The wakefulness switch: orexin, type 1 narcolepsy and where the drug acts
From the missing signal to where the new drug acts, in three steps.
1 — Healthy brain
The orexin neurons release the molecule: the wakefulness switch is on.
2 — Type 1 narcolepsy
Those neurons are gone: with no orexin, the switch flips off at the wrong moment (sleep attacks, cataplexy).
3 — With oveporextonOX2R
The drug occupies orexin receptor 2 in place of the absent molecule: the switch comes back on.
Source: own diagram, built from the literature on the orexin system (see the sources).
It is a tablet taken twice a day. The approval rests on two twelve-week phase 3 trials (randomised, double-blind, placebo-controlled) with 273 patients in total. The primary endpoint in both was the Maintenance of Wakefulness Test (MWT), which uses an electroencephalogram to measure how long someone takes to fall asleep across four 40-minute sessions; in one trial it ran alongside the Epworth Sleepiness Scale. The FDA approved not one dose but two regimens: 1 mg or 2 mg on waking and the same again three to five hours later, capped at 4 mg a day. By week twelve that latency had risen by 15.9 minutes in the 2 mg arm of the first trial —the 1 mg arm rose 12.5— and by 19.1 in the second, which tested only the 2 mg twice-daily regimen; on placebo it fell by about a minute. The difference against placebo was 17.2 minutes (95% CI: 13.7 to 20.7) and 20.1 (95% CI: 16.6 to 23.6), with p < .001 in both. The FINI questionnaire, which patients fill in themselves, was a secondary endpoint: in its cognitive function domain, those treated improved by 37.9 and 30.2 points more than placebo on a scale of 0 to 100. Why this matters more than it looks: orexin had been a target since it was described in 1998, twenty-eight years ago, and until now no approved drug activated its receptors. The drugs that already acted on them, approved for insomnia since 2014, block them.
These figures come from the United States public trials registry, where the sponsor deposits them. The primary results of both trials were published in the New England Journal of Medicine on 9 September 2026. The figure Takeda put out when it presented them at a conference — around 70% of patients with no cognitive difficulties, against around 15% on placebo — does not come from the registry but from the company itself: it is an interested party and it is not used here. And there is something that cuts the other way: safety. The FDA label gives as the most frequent adverse reaction the exact opposite of what the drug is for: insomnia in 60% of patients on 2 mg twice daily and 55% on 1 mg, against 1% on placebo. Urinary adverse reactions appeared in 63% of treated patients, and asymptomatic creatine phosphokinase elevations above five times the upper limit in 11%, against 5% on placebo. It is contraindicated with strong CYP3A inhibitors, carries three warnings — insomnia, urinary frequency and urgency, and CPK — and the label itself says it “has potential for abuse”. With the qualification the label also gives and that is worth keeping: about 90% of the insomnia started in the first two days, 63% resolved within a week and 17% was still ongoing when the study ended; none was serious or led to leaving the trial, and discontinuation for an adverse reaction ran at 2.6% against 1.3% on placebo. The drug that gives wakefulness back has trouble sleeping as its commonest effect.
A word on scope, though. This is a United States approval, and approved does not yet mean on the shelf. The DEA has yet to schedule it under the Controlled Substances Act. Takeda expected that scheduling within ninety days of approval; on 29 October 2026 it was still pending, and as of 4 November the US Federal Register carried no DEA scheduling for the drug. When it comes, the drug will be dispensed through specialty pharmacy, not the pharmacy down the road. China’s NMPA had approved it earlier, on 22 July 2026, and Japan’s MHLW on 24 August: three countries now. It is not yet approved in Europe, and Takeda’s announcements do not say whether it has applied to the EMA, only that other applications are underway. Type 1 narcolepsy is a rare disease, so this does not change many lives overnight; what changes is the approach.
For the first time, treatment is not chasing the symptoms one by one: it turns the switch that had gone off back on.
For years, narcolepsy patients were given something for the sleep, something for the cataplexy, something to get through the day. With oveporexton, for the first time, a single mechanism sits behind the improvement: the missing signal, restored.
Correction · 4 November 2026
Correction. On 4 November 2026 the facts in this piece were checked against their sources and the following was changed:
- Headline: it said “the cause of narcolepsy”. The drug is approved only for type 1 narcolepsy, and the FDA speaks of the cause of type 1.
- Trials: it said “273 adults”. The first trial included patients from age 16 (FDA label). It now says “273 patients”.
- It said that until now nobody had turned orexin into a treatment. Since 2014 the FDA has approved three insomnia drugs that act on its receptors and block them (DEA, Federal Register). Oveporexton is the first approved drug that activates them.
- DEA: it said Takeda expects scheduling within ninety days of approval. That window has passed. On 29 October it was still pending (Takeda), and as of 4 November there was no scheduling in the Federal Register.
- Europe: it said the application to the EMA had not been filed and was expected later in 2026. That had no source. Takeda’s announcements do not say whether it has applied to the EMA.
- Removed that the new approach “opens the door to treating other conditions by going after the cause instead of the symptom”. It had no source.
- Insomnia: added that 17% of cases were still ongoing when the study ended (FDA label).
- Sources: removed NeurologyLive, STAT and FiercePharma, listed with no link or date, and the repeated AASM entry. Added the FDA label and the orexin papers, which the chart caption pointed to but this list lacked, and the DEA and Takeda sources for this correction.
- Date: the piece was published on 20 August 2026, and in September later facts were added without marking it in the header, such as Japan’s approval on 24 August and the New England Journal of Medicine paper of 9 September. The header now carries the date of this correction.
Sources
- FDA — approval announcement for Orzeyful (oveporexton), 5 August 2026 — primary.
- FDA — Orzeyful prescribing information, NDA 220860, label of 11 August 2026 — accessdata.fda.gov. Primary. The two dosing regimens and the 4 mg daily maximum come from here.
- Discovery of orexin/hypocretin: de Lecea et al., PNAS 95(1):322-327, 6 January 1998; Sakurai et al., Cell 92(4):573-585, February 1998. The link to narcolepsy: Chemelli et al., Cell, August 1999. Primary.
- American Academy of Sleep Medicine (AASM) — statement on the approval of Orzeyful for type 1 narcolepsy, 6 August 2026 — independent secondary.
- Dauvilliers Y et al., “Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials”, New England Journal of Medicine, 9 September 2026, DOI 10.1056/NEJMoa2601598. Primary: the peer-reviewed publication of the primary results of both trials.
- ClinicalTrials.gov — deposited results of the two phase 3 trials: NCT06470828 (168 participants) and NCT06505031 (105) — primary: the official registry, holding data deposited by the sponsor and not peer-reviewed. Every efficacy figure in this piece comes from here.
- Takeda — press release on the approval, 5 August 2026 — primary, interested source: used for the mechanism (OX2R agonist), the ninety-day window it expected for DEA scheduling and the specialty pharmacy; never for the size of the effect.
- Takeda — results for April to September 2026, 29 October 2026: approved in the United States, Japan and China; the US launch still awaits DEA scheduling. Primary, interested source. US Federal Register checked on 4 November 2026: no DEA scheduling for oveporexton.
- DEA, Federal Register — scheduling of suvorexant, 28 August 2014, and proposed rule on suvorexant, lemborexant and daridorexant, 11 August 2026: antagonists of both orexin receptors, approved by the FDA for insomnia (Belsomra, Dayvigo and Quviviq). Primary.